Decision Support

Ambient Clinical Analytics is a digital health and clinical decision support software company providing FDA Class II and CE Mark-approved solutions for acute care hospitals and health systems. The company specializes in real-time clinical analytics platforms that integrate with existing EHR workflows to reduce alert fatigue, prevent errors, and improve patient outcomes. Primary product lines include Sepsis DART™, an automated sepsis detection and treatment bundle monitoring system; AWARE Clinical Control Tower™, a centralized tele-ICU and clinical command center platform for remote monitoring and collaboration; AWARE Patient Surveillance™ (AWARE Patient View™), providing telehealth and remote patient monitoring via proprietary Clinical Mesh Network™ technology; AWARE Certain™, a clinical intelligence platform for standardized patient evaluation and treatment; and YES Board™, a patient flow management system designed to reduce wait times and length of stay. All platforms leverage clinically vetted rules, indicative and predictive analytics, and smart notifications to guide clinical teams through complex care processes. The company's solutions are designed for deployment across entire health systems and support both centralized and decentralized care models. Ambient markets to hospital administrators, ICU directors, infectious disease specialists, and nursing leadership. Products are commercially deployed in acute care settings and demonstrate compliance with CMS Sepsis-1 reporting requirements. The company emphasizes scientific validation and cost reduction through error prevention and improved care timeliness.

ResearchDx is a comprehensive diagnostic development and contract research organization (CRO) specializing in in vitro diagnostic (IVD) test development, validation, and commercialization. The company operates three integrated divisions: Contract Services (biomarker discovery, assay development, regulatory filings); Diagnostic Laboratory (CLIA/CAP/ISO 15189 accredited clinical testing under the PacificDx brand); and Diagnostic Manufacturing (ISO 13485:2016 and GMP-compliant kit manufacturing under the CustomDx brand). Core capabilities include custom molecular assay development (PCR, qPCR, ddPCR, NGS, microRNA, protein, flow cytometry, ELISA), analytical and clinical validation, companion diagnostic development, and complete laboratory accreditation consulting. The company is ISO 13485:2016 certified, CLIA approved, CAP accredited, and FDA registered. Recent achievements include FDA 510(k) clearances for GlutenID celiac genetic health risk test and regulatory approvals for companion diagnostics (ProMarkerD for diabetic kidney disease, FibroSIGHT for MASH liver fibrosis detection). ResearchDx serves pharmaceutical companies, diagnostic startups, and established laboratories requiring integrated IVD development from concept through commercialization and contract manufacturing.

AirStrip Technologies develops clinical surveillance and alarm management software that consolidates siloed clinical data from EMRs, bedside monitors, and medical devices into vendor-agnostic mobile and web applications. The platform provides real-time patient monitoring with embedded waveforms, automated protocol management, and visual decision support across ICU, Emergency, Obstetrics, Cardiology, and Rapid Response units. Core capabilities include multi-patient monitoring (up to 40 patients per screen), diagnostic-quality 12-lead ECG capture with STEMI notifications, maternal and fetal waveform monitoring with real-time visualization, and comprehensive alarm triage and analytics. The software features digitized peer-reviewed clinical protocols, alarm trend analysis and responsiveness metrics, and context-aware clinical linking. AirStrip integrates with diverse hospital infrastructure systems while maintaining HIPAA compliance and meeting ISO 27001 security standards. The platform supports telemetry optimization workflows, door-to-balloon time reduction for acute coronary syndromes, and multi-unit alarm management at scale. Named one of TIME's World's Top HealthTech Companies in 2025 with an "outstanding" rating.

Guardant Health is a precision oncology company specializing in blood-based liquid biopsy testing for cancer detection, staging, and treatment monitoring. The company develops and commercializes circulating tumor DNA (ctDNA) tests that enable early cancer screening and inform treatment decisions across all stages of disease. Their primary product lines include Shield (cancer screening via blood test), Guardant Complete (advanced cancer oncology testing), and BioPharma Solutions for drug development and clinical trials. With over 500,000 tests performed and 12,000 physicians utilizing their platform, Guardant Health provides data-driven insights to improve clinical outcomes through biomarker analysis and minimal residual disease (MRD) detection. The company operates a CLIA-certified laboratory in the Bay Area and maintains regulatory compliance for commercialized diagnostics. Their technology supports personalized cancer care by identifying genetic mutations, tumor characteristics, and treatment response markers from blood samples, reducing reliance on invasive tissue biopsies and enabling earlier intervention.

VivoSense Inc. is a wearable sensor Contract Research Organization (CRO) specializing in digital health technology (DHT) for clinical trials. Founded 14+ years ago, the company provides end-to-end wearable sensor services across 20+ therapeutic areas, serving pharmaceutical sponsors, contract research organizations, and digital health innovators in 30+ countries. The company's core offering includes DHT strategy consultation, wearable device selection and vendor management, protocol development, data collection operationalization, data cleaning and analysis, and clinical validation. VivoSense operates a proprietary DHT platform designed for compliance and auditability in clinical trial environments. The platform enables collection and processing of high-volume, complex sensor data into structured, actionable insights. The company has deployed 70+ wearable sensors to date across diverse disease areas. Clinical operations and data science teams leverage decades of combined experience in digital health technology implementation and sensor data analytics. Recent regulatory engagement includes qualification discussions with the European Medicines Agency (EMA) regarding MEADOW-RETT-BR, a DHT-based measure of apnea events in Rett syndrome patients. Notable partnerships include Biogen, Roche, argenx, Mayo Clinic, and GSK. Services span three phases: study startup (DHT strategy and measure selection), study conduct (operationalization and data collection), and study closeout (data investigation and statistical validation).

Simple HealthKit is a healthcare infrastructure platform that delivers end-to-end solutions for member engagement, health screening programs, and connected care delivery. The company operates CLIA-certified laboratory infrastructure and provides vertically integrated screening services paired with digital patient engagement tools. Their platform serves health plans, biopharma companies, public health agencies, and retail pharmacy partners. Simple HealthKit specializes in closing HEDIS gaps, improving Star Ratings, and launching preventive care programs rapidly—typically deployable within weeks. The platform combines AI-driven digital-first tools with high-touch, at-home screening programs, supporting enrollment, screening workflows, and longitudinal patient engagement. Their enterprise-ready software integrates with existing health systems and provides real-time analytics, participation tracking, and audit-ready reporting. Clients include major health plans, insurers, retailers (Walmart, Amazon, CVS Pharmacy), state health departments, and public health organizations. The company emphasizes clinical accuracy through CLIA-certified lab operations while maintaining consumer-friendly, accessible healthcare experiences.

Medidata is a leading cloud-based clinical trial management platform owned by Dassault Systèmes. The company provides an integrated software suite that connects patient, data, and study experiences across the entire clinical research lifecycle. The platform leverages AI and automation to streamline clinical trial operations, including patient engagement, electronic data capture, data management, regulatory submissions, and study oversight. Medidata's solutions serve pharmaceutical sponsors, contract research organizations (CROs), and clinical research sites globally. The platform has been used in over 100,000 clinical trials and processes billions of data points annually. Key capabilities include AI-driven study design and build automation, clinical data management with advanced analytics, real-time data quality monitoring, and patient experience tools designed to reduce burden and improve enrollment and retention. The company is trusted by major life sciences organizations and has achieved regulatory recognition, including FDA approval for novel drug submissions. Medidata operates as a Software-as-a-Service (SaaS) provider with a focus on accelerating clinical trial timelines, reducing costs, and improving data integrity. The platform integrates with existing clinical trial ecosystems and supports multi-study, multi-therapeutic area deployments.

PerciX Corp is a healthcare AI software company that develops AI-powered platforms for transforming clinical workflows through computer vision and multimodal motion analysis. The company's flagship product, PerciX™ PT Copilot, is an intelligent physical therapy workflow platform that integrates real-time AI motion analysis, automated care plan generation, documentation automation, and outcome measurement into a unified clinical interface. The platform is FDA-listed (Class II, 510(k)-exempt) and designed to enhance clinician capabilities rather than replace professional judgment. PerciX's technology uses RGB camera input, cloud-based processing via NVIDIA GPUs, and proprietary machine learning models to deliver continuous patient monitoring and objective biomechanical data within existing clinical workflows. The company is built on HIPAA-compliant architecture with encrypted data protection. Beyond physical therapy, PerciX is conducting pioneering research in motion-based early detection of pediatric neurological conditions and hyperspectral imaging for non-invasive biomarker detection. The platform has demonstrated measurable clinical and business impact, including improved patient engagement (NPS > 9/10), enhanced billing code capture, and increased clinic efficiency. PerciX's founding team includes veterans from Intel (CEO with 30+ years platform engineering experience, CTO with 25+ years healthcare AI expertise), clinical expertise from an experienced DPT and clinic owner, and advisors from healthcare finance, engineering, and product strategy backgrounds. The company serves physical therapy clinics, rehabilitation facilities, and broader healthcare settings seeking to integrate objective motion analysis and AI-assisted documentation into evidence-based clinical care.

Mahe Medical USA operates a proprietary healthcare AI platform that integrates fragmented hospital systems to deliver real-time, actionable intelligence for cost reduction, revenue optimization, and clinical decision-making. The platform combines internal hospital data (EHR, billing, imaging, inventory, clinical notes, physician behavior) with external intelligence (FDA data, HHS compliance, supply chain, manufacturing costs, outcomes trials, vendor data) to generate predictive insights and executable recommendations. The company maintains access to 135,000+ FDA-registered, medically equivalent devices, enabling hospitals to identify cost-effective alternatives, capture missed reimbursement, optimize coding, and enable new procedural care. The platform is fully HIPAA-compliant and trained on real manufacturing cost data, FDA registration data, and clinical/operational datasets. Mahe Medical operates its own LLM rather than relying on commercial AI models, continuously learning from industry datasets. The company demonstrates measurable impact: case studies show recovery of missed reimbursement (up to $53M+ in net revenue increase), infection risk reduction through device transition recommendations, and systematic cost optimization. The partnership model aligns incentives with hospital success—clients pay a nominal setup fee plus a percentage of verified savings and revenue increases, ensuring Mahe Medical is compensated only on measurable outcomes. The platform addresses a critical healthcare gap: most systems provide static data or historical reporting; Mahe Medical transforms that data into real-time situational awareness and context-driven recommendations that drive clinical and financial outcomes.

Soundable Health develops proprietary AI-based sound analysis technology that transforms ambient sounds and acoustic signals into digital audio biomarkers for clinical decision-making. The company's platform captures, analyzes, and converts sound data into actionable medical insights to support non-invasive diagnostics across multiple clinical fields. Their technology enables healthcare providers to leverage audio biomarkers—measurable acoustic indicators derived from patient sounds—to improve diagnostic accuracy, patient outcomes, and clinical workflows. The platform is designed for global deployment across healthcare settings, with applications spanning multiple specialties. Soundable Health has presented at major medical and technology conferences including the AUA Annual Meeting and SK AI Summit, and has been recognized as part of SK Telecom's K-AI Alliance, indicating growing clinical and commercial validation. The company positions itself at the intersection of audio signal processing, machine learning, and clinical diagnostics, addressing a gap in non-invasive, standardized acoustic measurement for healthcare.

CogniFit is a digital health platform offering scientifically validated cognitive assessment and brain training software. The company develops computerized cognitive testing batteries (CAB) and adaptive brain training games targeting 20+ cognitive domains including memory, attention, executive function, perception, and coordination. CogniFit serves multiple market segments: healthcare professionals (neuropsychological assessment and rehabilitation), clinical research (cognitive endpoints in trials), educational institutions (student cognitive evaluation), corporate wellness (employee mental health), and direct-to-consumer users. The platform includes personalized, difficulty-adaptive training programs backed by 20+ years of published research. CogniFit maintains clinical validation through partnerships with 6,501+ clinics and research institutions, generating detailed progress reports and cognitive age assessments. The software is available via web and mobile applications (iOS/Android). The company supports multiple account types for patient management, research participants, educational cohorts, family use, and employee wellbeing programs. CogniFit does not manufacture hardware devices but operates as a SaaS provider of cognitive health software with regulatory claims regarding cognitive training efficacy and digital therapeutics validation.

JLK Inc is a medical artificial intelligence company headquartered in Santa Clara, CA, specializing in AI-driven diagnostic solutions for neurological and oncological conditions. The company develops MEDIHUB, a comprehensive AI-based platform suite that processes multiple imaging modalities—including CT, CTA, MRI, MRA, digital pathology, endoscopy, X-ray, and mammography—to support clinical decision-making across stroke management and cancer detection. The MEDIHUB Stroke platform addresses the complete care continuum from acute-phase intervention to chronic-phase prognostic prediction, with integrated mobile applications enabling rapid diagnosis and treatment planning. MEDIHUB also covers dementia assessment and brain aging analysis, plus detection and analysis of 12 cancer types including prostate, breast, gastric, and colorectal cancers. JLK positions its technology as a workflow optimization tool designed to reduce door-to-treatment time in stroke management and improve patient outcomes through early, accurate disease detection. The company targets hospital systems, imaging centers, and diagnostic facilities requiring AI-powered image analysis and clinical decision support. No specific FDA 510(k) clearances, ISO certifications, or regulatory credentials are mentioned on the website.

Saladax Biomedical, Inc. is a biotechnology company specializing in therapeutic drug monitoring (TDM) assays for psychiatry and oncology. The company develops and manufactures rapid blood-level measurement tests that optimize drug dosing for essential medications prescribed by psychiatrists and oncologists. Key products include the My5-FU Assay for monitoring 5-Fluorouracil chemotherapy (Health Canada approved, May 2024) and MyCare™ Insite for clozapine monitoring with point-of-care testing capabilities, delivering results in hours rather than days. Saladax supports personalized medicine initiatives through companion diagnostics and clinical trial collaborations with pharmaceutical partners. The company's TDM solutions enable clinicians to confirm medication adherence, optimize dosing regimens, and reduce toxicity risks, improving patient outcomes in psychiatric and oncological care. International distribution partnerships expand access across multiple regions.

CliniComp International is a healthcare IT vendor specializing in integrated electronic health record (EHR) solutions with native artificial intelligence capabilities. The company provides a comprehensive System as a Service (SYaaS) model that bundles software, hardware, implementation services, training, ongoing support, and continuous optimization into a single transparent contract. CliniComp's New Era EHR Solution Suite covers inpatient, ambulatory, ancillary operations, and revenue cycle management (RCM) within a single unified platform. The system features native AI embedded throughout clinical workflows, real-time advanced analytics, and comprehensive medical device integration that automates data capture from hundreds of bedside devices directly into patient records. Key differentiators include: (1) true interoperability built into core architecture for longitudinal patient records; (2) all integration and services included upfront with no hidden costs; (3) rapid implementation achievable in months rather than years; (4) proven reliability with decades of continuous operation, including documented zero-downtime records exceeding 25 years at some facilities. CliniComp serves health systems of all sizes, including Veterans Affairs facilities, rural hospitals, and large academic medical centers. The company emphasizes reducing clinician administrative burden, improving care coordination, enhancing patient safety, and delivering measurable ROI. CliniComp has received industry recognition including the 2025 MedTech Breakthrough Award, Healthcare Technology Review Top 50 award, and the 2026 Trailblazer in Healthcare Technology Pinnacle Award for its SYaaS model innovation.

Ansh Labs, a VION Biosciences company based in Webster, Texas, is a specialized biotechnology firm founded in 2010 that develops, manufactures, and distributes high-quality immunodiagnostic assays, reagents, and ELISA kits for biomedical research and clinical diagnostics. The company leverages in-house antibody development and characterization capabilities to create immunoassays targeting clinically significant biomarkers. Ansh Labs offers validated ELISA immunoassays with rapid turnaround times, high specificity, and excellent sensitivity—supporting 24-month shelf lives and straightforward procedures. Core service offerings include contract development of custom immunoassays, immunoassay method development and validation, assay optimization, cross-reactivity testing, and preclinical biomarker testing. The company serves life science researchers, hospitals, commercial laboratories, and public health agencies, with particular expertise in areas such as cancer diagnostics, fertility biomarker testing, obesity research, and specialty assays for glucagon regulation and reproductive health. Following its acquisition by VION Biosciences in August 2024, Ansh Labs continues to maintain its team and product portfolio while expanding its service capabilities.

Screentec Oy is an ISO 13485-certified contract development and manufacturing organization (CDMO) specializing in printed electronics for medical devices and diagnostics. Founded in 1989 with over 35 years of regulated manufacturing experience, Screentec delivers end-to-end product commercialization services from concept design and R&D prototyping through mass production. The company manufactures wearable medical sensors, disposable ECG electrodes, diagnostic and microfluidic devices, point-of-care platforms, electrochemical sensors, and user interfaces for medical, industrial, and IoT applications. Screentec maintains full vertical integration—design, material conversion, process engineering, regulatory affairs—and complies with FDA 21 CFR Part 820, EU MDR, IVDR, and IEC 60601 standards. The company serves demanding healthcare environments, diagnostic device manufacturers, and industrial sectors requiring high-reliability flexible electronics and sensor solutions.

Cognito Health is a medical device manufacturer specializing in predictive, contact-free continuous patient monitoring systems for healthcare facilities. Founded in 2012 by physicians and engineers from MIT, Harvard, Stanford, and Taiwan, the company develops AI-powered patient safety solutions designed to reduce hospital-acquired conditions including falls, pressure injuries, and unassisted bed exits. The Cognito Health platform integrates sensor technology with predictive analytics to provide caregivers with actionable, real-time alerts before adverse events occur. Clinical evidence demonstrates up to 43% reduction in patient falls, 71% reduction in pressure injuries, and 92% improvement in nursing efficiency. The scalable solution can be deployed across single units or entire healthcare facilities, supporting acute care, post-acute care, and long-term care settings. The company addresses a significant market need, as falls alone cost U.S. healthcare systems over $50 billion annually. Cognito Health operates globally with offices in the United States and Taiwan, serving hospital systems, rehabilitation centers, and specialized care providers seeking data-driven approaches to patient safety compliance and operational efficiency.

Emano Flow is a FDA-registered, software-only remote uroflowmetry platform that leverages patented machine learning and advanced audio processing technology to enable non-invasive assessment of urinary health. Patients record urinations from their smartphone in a home setting; the system automatically calculates flow rate, volume, and voiding patterns. Results are securely shared with providers through a web portal and mobile apps for real-time monitoring, baseline assessment, treatment efficacy tracking, and routine check-ins. The platform integrates embedded IPSS symptom surveys and supports objective clinical decision-making while reducing in-office testing burdens. Reimbursable under existing CPT codes and HIPAA compliant, Emano Flow achieves >94% patient compliance and is deployed across major health systems including Mayo Clinic, Lehigh Valley Health Network, and Arizona State Urological Institute.

Click Therapeutics is a New York-based digital therapeutics company founded in 2012 that develops and commercializes prescription software medical treatments for psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. The company combines neuroscience with software engineering to create evidence-based digital treatments delivered via mobile platforms and prescribed by physicians. Click's core platform approach includes Prescription Digital Therapeutics (PDTs) and Software-Enhanced Drugs™ (Click SE™), which combine therapeutic software with pharmaceutical agents to enhance clinical outcomes. The company employs advanced AI and adaptive data science technologies, including its proprietary Clickometrics® platform, to personalize patient experiences and optimize treatment efficacy. Key FDA-cleared and investigational programs include CT-152 (Rejoyn™) for major depressive disorder, CT-132 for episodic migraine, and CT-155 for schizophrenia negative symptoms, supported by peer-reviewed clinical evidence and partnerships with major pharmaceutical companies including Otsuka Pharmaceutical and Boehringer Ingelheim.

Koios Medical is a healthcare technology company that develops FDA-cleared, CE-marked AI-powered software for ultrasound image analysis, focusing on early detection of breast and thyroid cancers. The company's proprietary SmartUltrasound® platform (Koios DS™) leverages deep learning algorithms trained on over 500,000 breast lesion ultrasound images to provide clinical decision support for radiologists and sonographers. The platform assists in detecting, classifying, and characterizing suspicious lesions, reducing missed cancers by approximately 10x while improving workflow efficiency. Koios Medical operates on an annual subscription model and partners with major OEMs including GE Healthcare and Philips for distribution across 101+ installation sites in 28 countries. The company's AI-driven approach enhances diagnostic accuracy and supports billable ultrasound procedures, enabling healthcare facilities to streamline cancer detection workflows.

Connexall is a vendor-neutral, device-agnostic healthcare software platform specializing in enterprise-grade alarm management and event notification systems. Founded in 1992 and based in Toronto with U.S. operations, the company serves over 1,000 hospitals and health systems globally. Connexall's core platform unifies hospital-wide interoperability, enabling real-time clinical communication, alarm management, and workflow automation without replacing existing technology investments. Key capabilities include mobile-enabled alarm notifications with intelligent escalation, secure clinical messaging, web-based protocol access, and integrated business analytics that extract actionable insights from connected systems. The platform supports clinical workflows by ensuring timely delivery of critical information, reducing clinical response times by up to 80%, and improving staff satisfaction. Connexall emphasizes customizable, data-driven solutions aligned with individual hospital governance structures and clinical requirements.

Athelas is a healthcare software company providing an integrated platform for revenue cycle management (RCM), electronic health records (EHR), and AI-powered clinical documentation. The company offers four primary products: (1) Athelas RCM (formerly RCM Insights), an AI-driven platform for claim management, denial defense, and revenue optimization through automated claim processing and predictive analytics; (2) Ambient AI, an intelligent medical scribe and copilot system that automatically generates clinical notes, CPT/ICD-10 codes, and compliance checks with real-time EMR integration; (3) Athelas Air, a modern EHR designed for ambulatory practices with features including AI-powered patient intake, autonomous receptionist, patient portal, pre-visit workflows, and integrated documentation; and (4) Athelas Agents, customizable AI assistants for scheduling, insurance authorizations, appeals, and data retrieval from external systems. The platform serves diverse healthcare organizations including urgent care, physical therapy, orthopedics, dermatology, ENT, and specialty practices. Key capabilities include automated remittance reconciliation, AI-powered portal data extraction, revenue analytics dashboards, parallel scribing for overlapping patient encounters, compliance nudges, and autonomous patient engagement. Customers report measurable outcomes including improved first-pass claim rates (95%+), increased collections ($17–$3.6M monthly), reduced denial rates (1–1.5%), and significant time savings (2+ hours per provider daily). The company emphasizes security, customization, and seamless EHR integration across major platforms.

Foresite Healthcare develops a passive, wearable-free monitoring platform designed for senior living communities and assisted living facilities. The solution provides continuous 24/7 gait analysis, vital sign trending, and sleep pattern monitoring to predict and prevent falls, detect acute illnesses (urinary tract infections, congestive heart failure, upper respiratory infections), and monitor cognitive decline. The platform uses advanced AI-driven predictive algorithms built on over 15 years of research and 20+ patented technologies. Core capabilities include fall risk prediction (up to three weeks in advance), instant fall detection with 97% accuracy and 7-second alert response, real-time vital sign analysis for early illness identification, sleep quality monitoring with restlessness tracking, and privacy-protected rewind analysis without facial recognition. The system is HIPAA-compliant and generates actionable insights through mobile-friendly dashboards to optimize staff efficiency and reduce manual monitoring burdens. Foresite serves senior communities, assisted living operators, and skilled nursing facilities, with documented results including reduced falls, decreased hospitalizations, improved length of stay, and enhanced caregiver workflows. The technology has been validated through clinical research and is deployed across multiple senior living organizations.

InfoBionic, Inc. is a virtual cardiac telemetry company specializing in AI-enabled remote cardiac monitoring. The company's flagship product, MoMe ARC® (Advanced Remote Cardiology), is recognized as the gold standard in remote cardiac ECG monitoring and represents the first platform to market with hospital-grade continuous monitoring capability deployable from nearly any location. The MoMe ARC® platform integrates advanced artificial intelligence to enhance clinical workflow, detect previously undetected cardiac anomalies, and enable rapid interventions at scale. InfoBionic offers a comprehensive suite comprising MoMe Solutions (AI-enabled ECG analysis), MoMe Sensors (interchangeable, tiered biosensor lead sets configurable for varying acuity levels from high-acuity diagnostics to portable monitoring), and MoMe Analytics™ (business intelligence and AI-embedded analytics for cardiac care operations). The company targets cardiology practices, cardiologists, electrophysiologists, medical leaders, hospital systems, and virtual health programs. InfoBionic has received FDA clearance for its MoMe ARC® Patch (announced August 2025), affirming regulatory compliance and clinical safety. The platform transforms cardiac data into actionable clinical insight through proprietary AI algorithms focused on arrhythmia detection, atrial fibrillation monitoring, and congenital heart disease assessment. Products are designed to improve patient quality of life through earlier interventions, enhance operational efficiency across departments, and support both enterprise and telehealth deployment models.

PASCALL SYSTEMS INC. is a Boston-based medical device company specializing in precision EEG-guided anesthesia management. The company develops a wearable brain monitoring platform that uses advanced signal processing and electroencephalography (EEG) to optimize intraoperative anesthetic administration. The platform aims to reduce unnecessary anesthetic exposure, thereby improving postoperative outcomes and preventing complications such as postoperative delirium (POD) and opioid dependence. The technology integrates real-time physiological data analysis, control engineering, and AI-driven decision support to empower anesthesiologists with personalized, data-driven anesthesia dosing. PASCALL's solution is designed to comply with FDA regulations and operates under rigorous quality management systems. The company focuses on signal extraction, artifact removal, and state-space modeling of brain activity to deliver clinically actionable insights during surgery.

Behavidence develops a patented mobile application that delivers scientifically validated daily mental health monitoring through digital phenotyping and machine learning. The platform measures mood, focus, worry, and stress by analyzing passive digital biomarkers derived from smartphone usage patterns without tracking message content, websites visited, or typing activity. The solution is designed for healthcare providers (psychiatrists, physicians), clinical trial sponsors, insurance companies, and individual users seeking objective, measurement-based mental health assessment. The app supports standardized psychiatric questionnaires including PHQ-9, GAD-7, and ASRS for structured clinical evaluation. Regulatory credentials include HIPAA compliance and CE marking. Data security employs AES-256 encryption with full user anonymization. The platform offers SDK integration for embedding into existing healthcare IT systems and remote monitoring capabilities to support early intervention strategies. Clinically validated research demonstrates the app's accuracy in detecting mental health deterioration and predicting adverse outcomes. Primary use cases include ongoing patient monitoring in clinical practice, real-time digital phenotype collection for trial efficacy endpoints, and insurance-based early intervention programs for cost reduction. The solution is available on iOS and Android platforms.

Huma is a UK-based global digital health company providing AI-driven cloud platform solutions for healthcare organizations, pharmaceutical companies, and research institutions. The Huma Cloud Platform (HCP) is a regulated, enterprise-grade infrastructure that enables rapid development and deployment of clinical applications including remote patient monitoring, virtual care, clinical trial data capture, and population health management. The platform integrates analytics, machine learning, and AI agents to transform connected health data into actionable clinical intelligence. Huma's applications span primary care (myGP, eConsult), secondary care (Aluna respiratory, GDm gestational diabetes, eTriage emergency), clinical trials (Alcedis), and public health (population screening, CVD risk assessment). The platform holds regulatory clearances across multiple jurisdictions (FDA 510(k) Class II, MHRA Class IIb, EU MDR, TGA, CDSCO, Saudi FDA, MDSAP) and maintains ISO 13485, ISO 27001, and SOC 2 Type II compliance. Huma supports 100+ applications built by clients, serving 100+ global organizations and approximately 100 million patients. The company's integrated delivery model includes discovery, deployment, and federated scale-up phases for healthcare transformation at national scale.

Sirona Medical is a cloud-native software company specializing in radiology image management, diagnostic reporting, and AI-driven workflows. The company develops Rad OS™, an integrated platform that unifies PACS (Picture Archiving and Communication System), reporting, viewer, and worklist functionality into a single browser-based operating system for radiologists. The platform leverages AWS cloud infrastructure to enable radiologists to read studies from anywhere without legacy on-premise servers or software downloads. Sirona's core offering includes: (1) PACS Archive—a fully managed AWS-backed system with 99.99% availability and no maintenance overhead; (2) Pixel-Powered Reporter—an AI-driven reporting engine using agentic AI, proprietary NLP, and a radiology-specific large language model (LLM) to auto-generate impressions and pre-draft structured reports; (3) Integrated Viewer with patented Ontology classification that organizes studies and auto-places measurements into reports; and (4) Unified Worklist aggregating multiple sites and systems with embedded AI for context prioritization. The company integrates all clinical data feeds (DICOM, HL7, speech) and employs multimodal AI capabilities including speech-to-action agentic agents that execute workflow tasks. Pixel-to-report functionality (auto-placement of findings into appropriate report sections) is noted as undergoing regulatory review. Sirona operates a business model serving radiology practices, imaging centers, and health systems. The company has raised $110M since inception, has 30+ contracted customers across 110+ integrated sites, and maintains partnerships with AI vendors (RevealDX, Koios) for specialized diagnostic capabilities such as lung cancer screening. The platform supports remote access via SpaceX Starlink and operates with HIPAA compliance on AWS infrastructure.

Diag-Nose.io is a Melbourne-based biotechnology company specializing in precision diagnostics and therapies for chronic respiratory diseases including asthma, COPD, and chronic sinusitis. The company's flagship RhinoMAP platform combines nasal microsampling, proteomics, and AI-driven machine learning algorithms to decode airway biology and provide actionable clinical insights for ENT physicians. By analyzing patients' immune profiles and airway biology, Diag-Nose.io delivers personalized treatment recommendations that move beyond trial-and-error respiratory care. The ABEL Microsampler® device enables non-invasive nasal liquid biopsies for research and clinical diagnostics, with recent FDA and ARTG regulatory approvals. The platform targets treatment personalization and disease prevention through root-cause analysis, supporting precision medicine approaches for improved patient outcomes in respiratory disease management.

Brain Tunnelgenix Technologies Corporation (BTT™ Corp.) is a MedTech innovator specializing in non-invasive, continuous brain temperature monitoring through proprietary brain thermal tunnel technology. Founded on discoveries by Dr. Marc Abreu (Harvard Medical School, Yale School of Medicine), BTT develops FDA-cleared devices and wearable systems that capture real-time brain thermodynamic signatures using advanced microsensors and artificial intelligence. The BTT™ Abreu 700 system represents the first clinically accurate measurement of human brain temperature without corrective factors. The company's integrated platform combines brain thermodynamics, IoT connectivity, and predictive AI models to support diagnosis, monitoring, and therapeutic applications across infectious diseases, neurodegenerative conditions (Alzheimer's, Parkinson's, Multiple Sclerosis), cancer, stroke risk, surgical outcomes, sleep optimization, and performance enhancement. Applications span clinical settings, hospital environments, home monitoring, and occupational wellness programs.

DeGen Medical is a medical device development and manufacturing company founded in 2011, specializing in innovative spinal care solutions for complex spinal disorders. The company develops advanced spinal implants and instrumentation using cutting-edge technologies including AI-driven augmented reality platforms and proprietary 3D printing processes. Their product portfolio includes the Solar AM anterior lumbar interbody fusion (ALIF) device and instrumentation designed for both open and minimally invasive spine surgeries. DeGen Medical serves orthopedic surgeons and surgical centers, targeting conditions such as vertebral compression fractures and motion preservation. The company combines clinical insights with advanced biomedical engineering to deliver world-class implants and patient-specific solutions that improve surgical precision and patient outcomes.

MEDITECH (Medical Information Technology, Inc.) is a privately held healthcare software company founded in 1969, headquartered in Westwood, Massachusetts. The company specializes in developing and supporting integrated electronic health record (EHR) systems and health information technology solutions for healthcare organizations worldwide. MEDITECH serves approximately 2,400 healthcare sites across the United States, Canada, and the United Kingdom, holding a significant share of the U.S. hospital EHR market. The company's flagship product, MEDITECH Expanse, is a web-based EHR platform featuring cloud deployment, mobile access, point-of-care documentation, patient communication tools, and secure patient health portals. MEDITECH is advancing AI-infused EHR solutions to enhance healthcare delivery, improve physician experience, increase operational efficiency, and support predictive analytics and genomics applications. The platform emphasizes data accessibility and interoperability, enabling healthcare leaders to leverage analytics for performance monitoring, clinicians to make data-driven decisions, and patients to benefit from improved care coordination and engagement. MEDITECH maintains partnerships with major technology firms and continues to evolve its services to meet the diverse needs of health systems ranging from large hospital networks to independent community healthcare organizations.

CareTech Human manufactures FDA-registered, sensor-enabled medical devices for urology and remote patient monitoring. The company's flagship product simplifies uroflowmetry procedures through user-friendly technology integrated with automated symptom severity scoring and AI-powered data processing. The system enables objective health assessment with real-time patient compliance tracking, generating clinical-grade data suitable for both hospital and home use. CareTech's solution supports evidence-based clinical decision-making by delivering precise, actionable metrics while facilitating reimbursement through recognized remote monitoring codes. The platform prioritizes health data security and privacy, with clinical trial-ready technology designed for seamless integration into existing hospital workflows and urology practices.

neotiv GmbH is a German digital health company founded in 2017, headquartered in Magdeburg and originating from Otto von Guericke University and the German Centre for Neurodegenerative Diseases. The company develops a sophisticated digital platform delivering proprietary cognitive assessments for early detection and longitudinal monitoring of neurodegenerative diseases, particularly Alzheimer's disease. neotiv's platform combines neuroscience research with mobile software (smartphones and tablets) to provide user-friendly, remote cognitive testing capabilities. The core product suite includes neotivCare—a healthcare-certified solution for clinical cognitive impairment monitoring—and a customizable cognitive assessment battery that tracks Alzheimer's-specific cognitive signatures through validated neuropsychological tests and health questionnaires. The platform features neotivTrials, a web portal enabling researchers and physicians to design individualized study configurations with direct app deployment for mobile or on-site assessments. Applications span clinical research, drug development support, diagnostic support, and patient monitoring in hospital and research settings. The platform is validated for medical use and integrated into clinical workflows globally.

Calla Health Foundation is a medical device company focused on improving women's access to cervical cancer prevention and screening, particularly in low-resource settings. The organization develops portable, affordable diagnostic imaging technologies and AI-driven decision support systems designed to democratize gynecological examination and cancer prevention. Their product suite includes the Pocket Colposcope (a portable, low-cost video colposcope for cervical tissue examination), the Callascope (a speculum-free cervical imaging device enabling self-screening or provider-assisted insertion), and CARE (an AI algorithm for cervical pre-cancer risk assessment). The company's innovations enable midwives and community health workers to perform point-of-care screening and "see-and-treat" management paradigms without requiring traditional hospital infrastructure or specialized physician expertise. FDA-cleared and clinically validated in multiple low- and middle-income countries.

Microbiologics is a leading provider of biological reference materials, quality controls, and contract research organization (CRO) services for microbiology, molecular diagnostics, and virology. Founded over 50 years ago and headquartered in Saint Cloud, Minnesota, the company serves healthcare and life science laboratories, diagnostic manufacturers, and biopharmaceutical companies globally. In microbiology, Microbiologics offers the industry's largest collection of reference strains in ready-to-use formats including KWIK-STIK™, EZ-Accu Shot™, Epower™, and LYFO DISK™ products for quality control of growth promotion testing, enumeration methods, and antimicrobial effectiveness testing. The company provides custom microbiology services including environmental isolate controls, antimicrobial assays, microbiome testing, and proficiency testing solutions. In molecular diagnostics, Microbiologics manufactures external third-party IVD quality controls and reference standards under the Helix Elite™ brand for infectious disease diagnostics (respiratory, STI/women's health, gastrointestinal, healthcare-associated infections) and oncology (gDNA, cfDNA/ctDNA, FFPE). Virology capabilities include BSL-2 and BSL-3 contract research laboratories offering custom and off-the-shelf viral stocks, recombinant virus production, adventitious virus panels, viral assay development, and antiviral drug and vaccine testing services. The company maintains ISO 17025 accredited facilities and provides certified reference materials (CRM) for regulated laboratory environments. Microbiologics serves IVD manufacturers, pharmaceutical companies, clinical diagnostic laboratories, and research institutions across North America, Europe, and globally.

Clario (formerly Bioclinica) is a global clinical trial endpoint technology platform and services provider with 50+ years of expertise supporting drug development. The company delivers comprehensive solutions for efficacy, safety, and patient quality-of-life assessments across decentralized, hybrid, and site-based clinical trials in over 100 countries. Clario's integrated platform combines clinical trial management software, connected medical devices, and AI-powered solutions spanning cardiac safety monitoring, electronic clinical outcomes assessment (eCOA), medical imaging with imaging core lab services, precision motion analysis, and respiratory endpoints. With experience managing 30,000+ trials contributing to 700+ FDA/EMA new drug approvals, Clario employs 3,900+ professionals including 200+ therapeutic area specialists. The platform emphasizes regulatory compliance, patient-centric design, global multilingual deployment, and 24/7 operational support to simplify trial processes for sponsors, contract research organizations (CROs), and research sites.

Visual Medica is a cloud-based PACS (Picture Archiving and Communication System) and RIS (Radiology Information System) software provider founded in 1998, serving radiology centers and diagnostic imaging facilities across Latin America. The company offers fully web-based, cloud-hosted or on-premise solutions including VM PACS VNA for DICOM image storage and visualization, VM RIS Gestión ERP for integrated radiology workflow and administrative management, VM Medical Workstation for diagnostic image processing, and VM Clinical Viewer for remote access. Visual Medica's flagship offering is its AI Marketplace—an integrated platform combining RIS, PACS, medical administration, and artificial intelligence-powered diagnostic support tools, including VM Speech (medical speech recognition) and structured reporting assistance. The platform is designed to streamline imaging workflows, improve diagnostic accuracy, and enhance operational efficiency. With over 1,500 installations across Latin America and FDA clearance, Visual Medica serves hospitals, diagnostic centers, and imaging practices of varying sizes.

BEE Medic is a global supplier of high-precision EEG-based medical equipment and software for neurofeedback, biofeedback, diagnostics, and EEG research. The company serves licensed mental health professionals, clinicians, and research institutions with FDA-cleared, modular systems developed in collaboration with clinical partners and research institutions. BEE Medic's product portfolio includes the NeuroAmp II amplifier family for EEG recordings, the Sync Box for ERP synchronization, and the Combi Sensor for biofeedback measurements. Software platforms such as Cygnet and BEE Lab support various neurofeedback training protocols and real-time brainwave feedback applications. The company operates as part of the BEE Group AG network with offices in the USA, Germany, Switzerland, and the UK, and provides comprehensive support including hands-on training courses, technical assistance, and clinical education to help practitioners implement neurofeedback therapies for ADHD, chronic pain, autism, PTSD, and other conditions requiring brain self-regulation.

Signos is an AI-powered metabolic health platform that combines continuous glucose monitoring (CGM) with personalized weight management guidance for non-diabetic and metabolically-conscious consumers. The platform integrates Dexcom G7 CGM sensors with a proprietary mobile application that uses machine learning to analyze glucose patterns and predict individual metabolic responses to food, exercise, sleep, and stress. Members receive real-time glucose tracking, personalized eating and movement recommendations, registered dietitian support, and weekly metabolic reporting. The service is FDA-cleared and HSA/FSA-eligible, offered through direct consumer channels and employer-sponsored wellness programs. Clinical outcomes show 86% of members report success in their first month, with significant weight loss and improved metabolic stability.

Akili Interactive is a digital medicine company that develops prescription and over-the-counter video game–based treatments for cognitive impairments, particularly ADHD. The company combines neuroscience research with interactive gaming technology to deliver therapeutic interventions through engaging digital experiences rather than traditional pharmaceutical or device-based approaches. EndeavorRx is the company's FDA-authorized prescription digital therapeutic for children with ADHD; EndeavorOTC is a clinically validated over-the-counter game-based treatment for adults with ADHD, available on iOS and Android platforms. Akili's platform represents a novel therapeutic class—digital medicine—designed to improve attention, focus, and quality of life. The company's proprietary technology integrates clinical efficacy data with game design to create accessible, engaging treatment experiences. Products are delivered directly to patients via consumer app stores and through prescription channels, with clinical evidence supporting cognitive improvements in ADHD populations.

Vivid Vision Inc develops digital vision care solutions for diagnosis and therapeutic training of binocular vision disorders and visual field assessment. The company manufactures two core platforms: Vivid Vision (VV), an advanced vision training system for amblyopia, strabismus, and convergence insufficiency delivered via VR-based home training; and Vivid Vision Perimetry (VVP), a precision at-home microperimetry system for clinical visual field testing in retinal and glaucoma disorders. VVP is validated for use as a functional vision endpoint in clinical trials for geographic atrophy, age-related macular degeneration, and glaucoma therapeutics. The company also offers EYEBAB VT, a therapeutic exercise platform with dozens of vision activities for clinic-based intervention. With over 100,000 patients in 50+ countries since 2014, Vivid Vision systems are used by major ophthalmic pharmaceutical companies and leading research institutions. Published studies demonstrate VVP achieves 6.8× better precision than standard automated perimetry, 2× better fixation stability, and 99% adherence to at-home testing protocols. The platform has been evaluated by premier institutions including the Retina Foundation of the Southwest and Duke University Medical Center. Vivid Vision Perimetry is clinically validated and industry-ready for phase I and II ophthalmology trials.

bioMérieux is a global in vitro diagnostics leader headquartered in France, with significant US operations. The company manufactures and distributes comprehensive diagnostic solutions for clinical microbiology, molecular pathology, blood culture detection, immunoassays, and rapid point-of-care testing. Core competencies span microbial identification and antimicrobial susceptibility testing (ID/AST), sepsis diagnosis and management, infectious disease detection (respiratory pathogens, gastrointestinal pathogens), and blood culture systems. Key product platforms include BIOFIRE® FILMARRAY® multiplex PCR systems, VITEK® MS PRIME mass spectrometry, BACT/ALERT® VIRTUO® blood culture automation, and VIDAS® immunoassay analyzers. The company also serves pharmaceutical and food safety markets with quality control and environmental monitoring solutions. bioMérieux addresses critical clinical challenges including antimicrobial resistance (AMR) stewardship, rapid sepsis identification, and respiratory infection diagnostics. Offerings span hospital laboratories, point-of-care settings, and industrial applications. The company emphasizes diagnostic-driven clinical decision support, workflow automation, and integrated laboratory information management. Manufacturing includes automated detection systems, rapid molecular platforms, and MALDI-TOF mass spectrometry instruments. US operations distribute test kits, reagents, and instruments through multiple channels including direct sales and the bioMérieux eShop. The company holds multiple regulatory clearances including FDA 510(k) approvals and CE marking for diagnostic instruments and test kits.

Ceribell develops point-of-care EEG systems for rapid seizure detection and monitoring in critical care settings. The company's flagship product, a portable EEG platform integrated with the CLARITY® AI algorithm, enables bedside detection of seizure activity, including non-convulsive seizures, in ICUs, emergency departments, and neurology units. CLARITY® is FDA-cleared for pediatric and neonatal patients, representing the first and only FDA-cleared seizure detection algorithm for newborns preterm and up. The system delivers 95% sensitivity and 97% specificity for status epilepticus detection with 99.9% negative predictive value. Ceribell's secure cloud portal features FedRAMP High cybersecurity authorization for telemedicine consultation and remote EEG interpretation. Clinical evidence demonstrates the platform is associated with 4.1-day shorter median ICU stays and improved neurological outcomes compared to conventional EEG workflows. The company supports hospitals with ongoing in-person and virtual training. Target markets include intensive care units, emergency departments, and neurology departments in acute-care hospitals. Ceribell holds multiple FDA clearances (510(k)), CE mark certification, and has published 45+ peer-reviewed publications validating diagnostic accuracy and clinical utility in critical care populations.

Beacon Biosignals is an AI-driven neurotechnology company specializing in clinical-grade sleep EEG capture and biomarker analysis for drug development and clinical research. The company develops FDA-cleared headband devices (Dreem 3S) that collect high-fidelity sleep electroencephalography data in home and clinical settings, paired with proprietary AI algorithms trained on 200,000+ hours of EEG recordings. Beacon's end-to-end platform supports translational research, clinical trial optimization, and real-world clinical practice across psychiatric disorders (major depressive disorder, schizophrenia, bipolar disorder), neurological conditions, and primary and secondary sleep disorders. The company provides quantitative sleep endpoints and pharmacodynamic biomarkers to identify dose-dependent drug effects, characterize and stratify patient populations, support label expansion claims, and track disease progression. Services include full-service clinical trial support with Clinical Study Operations and Scientific Services teams managing device setup, software integration, data quality assurance, and regulatory reporting. Beacon's technology enables objective measurement of sleep architecture and brain function, reducing participant and site burden compared to traditional methods. The platform integrates secure data upload, low-latency event monitoring for compliance and treatment response assessment, and analytics for cohort identification. Beacon is backed by significant venture funding (Series B upsized to $97 million+ as of April 2026) and serves pharmaceutical development, clinical research organizations, and academic institutions. Products are restricted to clinical trial, diagnostic, and academic research use and are not available for individual consumer purchase.

inHEART develops an AI-enabled digital twin platform for cardiac care, specializing in image-guided ablation procedures for ventricular tachycardia (VT) and other arrhythmias. The company's core offering is a proprietary segmentation algorithm that analyzes CT and MR images to create detailed 3D anatomical cardiac models, enabling precise identification of arrhythmogenic tissue and substrate characterization. The platform integrates seamlessly with all major electroanatomic mapping (EAM) systems for real-time procedural guidance. Clinical evidence demonstrates 60% reduction in procedure time and 38% reduction in recurrence rates for VT ablations. inHEART serves 300+ partner hospitals across 40+ countries, with 7,500+ supported cases. The company maintains regulatory compliance including SOC 2 and HIPAA certifications. Based in France (Bordeaux/Pessac) with a US office in Cambridge, MA, inHEART operates at the intersection of advanced imaging analytics, AI, and interventional cardiology. The platform has been featured in major cardiac electrophysiology symposia and publications, with endorsements from leading academic electrophysiologists. Recent funding (2024) and board leadership appointments signal continued investment in platform expansion and global market penetration. Target users include cardiac electrophysiologists, interventional cardiologists, and hospital EP labs managing complex arrhythmias.

Curio Digital Therapeutics develops AI-driven digital-first behavioral health solutions specifically for women's mental health across fertility, pregnancy, postpartum, and menopause life stages. The company offers Prescription Digital Therapeutic (PDT) products FDA-authorized for postpartum depression treatment, complemented by coaching and therapist-supported programs. Core offerings include MamaLift and MamaLift Plus, on-demand digital therapy platforms featuring evidence-based cognitive behavioral therapy (CBT) lessons, health trackers, and live health coach support. Curio-I is an AI-powered predictive platform for early identification and risk stratification of mental health disorders affecting women. All products are validated through clinical trials, with seven published studies demonstrating clinical efficacy. The platform operates on cloud-first, mobile-first architecture enabling anytime, anywhere access. Early adopters and partners include Mount Sinai Health System, Columbia University, and various health plans. The company has received recognition from Business Insider, BioNJ, and innovation awards including Point32 and MassChallenge. Product outcomes show 2 of 3 women achieving symptom improvement below depression thresholds, 70% user referral rates, and 5:1 return on investment metrics.

LVIS Corporation is a San Francisco Bay Area–based medical technology company specializing in neural information analysis and EEG diagnostics software. The company develops patented brain-imaging visualization and analysis technologies that decode brain network activity to support neurological disease diagnosis and clinical workflows. LVIS's flagship product is NeuroMatch®, a cloud-based SaaS platform that automates and enhances EEG examination, source localization, and 3D/4D brain visualization. NeuroMatch has received FDA 510(k) clearance (K250239) in the United States and MFDS regulatory clearance in South Korea. The platform addresses critical gaps in neurological healthcare capacity: the shortage of neurologists (1 per 23,259 people), sub-optimal clinical workflows, and surging demand for neurological diagnosis. LVIS is backed by prestigious academic partnerships, including Stanford Byers Center for Biodesign Faculty Fellowship, Stanford StartX incubator, and NVIDIA Inception Program support. The company has received research grants from the Stanford Spectrum Center, LivaNova, and the Epilepsy Foundation. Leadership includes neuroscience and engineering experts; the company was founded by Jin Hyung Lee, PhD. NeuroMatch was named a 2026 Edison Awards finalist. The company operates with headquarters in Palo Alto, California, and additional offices in Gangnam and Daegu, South Korea, serving both US and international markets.

GrayMatters Health develops Prism, an interventional psychiatry software platform that leverages fMRI-informed digital biomarkers and EEG neurofeedback to deliver personalized psychiatric care. The company's core technology uses real-time brain activity monitoring via EEG sensors to help patients self-regulate neural patterns associated with mental health conditions. Prism offers clinically validated protocols for PTSD (utilizing amygdala-based biomarkers) and Major Depressive Disorder (targeting ventral striatum reward-system activity). The platform integrates into clinical workflows, allowing technicians to administer sessions under clinician supervision, optimizing operational efficiency. GrayMatters emphasizes evidence-based design with published clinical studies demonstrating efficacy in symptom reduction and improved patient outcomes. The company provides comprehensive support including onsite installation, staff training, and ongoing technical assistance. Prism represents a bridge between neuroscience research and accessible psychiatric practice, enabling clinicians to augment standard-of-care therapies with objective, brain-derived biomarker data. The technology is designed for clinic deployment with minimal storage footprint and seamless integration into existing treatment protocols.

EntroGen, Inc. is a molecular diagnostics company specializing in oncology and personalized medicine solutions. The company develops and manufactures FDA-approved and research-use-only (RUO) PCR-based assays for cancer biomarker detection, companion diagnostics, and minimal residual disease (MRD) monitoring. Core product portfolio includes the CRCdx® RAS Mutation Detection Kit (FDA-approved companion diagnostic for KRAS and NRAS mutations in colorectal cancer), NPM1 One-Step MRD Kit for acute myeloid leukemia detection, DPYD Genotyping Kit for pharmacogenomic assessment, and Microsatellite Instability (MSI) Detection Kit. EntroGen manufactures the Benchbot® 4800 laboratory automation platform designed to streamline workflow from sample preparation to PCR plate setup in four steps. The company offers three integrated product lines: automation equipment, molecular reagents/assays, and analysis software. All products are manufactured to ISO 13485 quality standards. EntroGen serves clinical laboratories, hospital pathology departments, and oncology centers globally, supporting treatment decision-making through molecular testing. The company participates in industry conferences including the World Clinical Biomarkers & Companion Diagnostics Summit, indicating active engagement in the molecular diagnostics and precision oncology markets.

Strados Labs is a respiratory-focused clinical trial solutions company delivering regulatory-grade endpoint data for pharmaceutical and biotech sponsors through Phase I–IV trials across 34 countries. The company specializes in continuous, ambulatory respiratory monitoring combined with AI-driven analysis and expert human review to capture disease burden between clinic visits. Product offerings include the Air Next Spirometer (FDA-cleared spirometry with FEV₁, FVC, FEV₁/FVC measurement), RESP® Biosensor (FDA 510(k)-cleared wearable capturing high-fidelity cough, lung sounds, vitals, and activity), RESP® Watch (clinical-trial-ready cough and activity monitoring), NObreath® FeNO (point-of-care fractional exhaled nitric oxide for airway inflammation assessment), and eCOA software suite (ePRO, eClinRO, eObsRO for electronic patient-reported and clinician-reported outcomes). Strados recently acquired NuvoAir's clinical trial business to expand its integrated endpoint platform. All devices are FDA 510(k) cleared, CE-marked, and ISO 13485 certified. The company has accumulated 87,000+ hours of respiratory data across 55+ clinical studies and published 70+ peer-reviewed papers in respiratory research journals including ERJ, CHEST, and npj Digital Medicine. Services include study design consultation, site support, device logistics, and GCP-compliant data delivery. The company serves pharma sponsors and contract research organizations seeking single-vendor respiratory endpoint solutions with retained audio, AI detection paired with expert review, and full audit trails for regulatory submission.

Aventusoft, LLC is a Boca Raton, Florida-based medical technology company specializing in signal detection analysis and AI-driven digital health platforms since 2010. The company develops innovative solutions focused on cardiac monitoring, clinical decision support, and decentralized clinical research. Primary product lines include Hemotag, a non-invasive cardiac monitoring device paired with AI analytics to reduce reliance on invasive cardiac imaging and implantable devices; CarePear, a digital health platform connecting patients and physicians with US-based sub-specialists through AI-enabled telemedicine; and Trialogy, an AI-driven platform for decentralized clinical trials that streamlines life science research. Aventusoft has received recognition from the NIH (RADx Tech for Maternal Health Challenge), DARPA, American College of Cardiology (ACC Innovation Showcase Award 2021 and 2023), and multiple design and innovation awards. The company demonstrated 146% two-year revenue growth and ranked No. 112 on Inc. Magazine's 2023 Southeast Region fastest-growing private companies list. Products target cardiac care, maternal health, specialist access, and clinical research domains, with regulatory focus on maternal health applications and AI-driven diagnostics.

Q Bio operates a preventive health clinic offering comprehensive diagnostic assessment and longitudinal health monitoring through an integrated platform combining MRI imaging, EKG, biometric measurement, genetic analysis, and wearable data integration. The company has developed a proprietary digital health platform that creates a 3D digital twin of patient biology, presenting nine biological subsystems through an interactive dashboard. The Q Exam, conducted at their Redwood City, California clinic, is a 75-minute comprehensive assessment that includes full-body MRI, ECG/EKG, biometric and vital signs collection, genetic measurements, and integration of wearable device data. The platform delivers AI-assisted analytics to support clinical decision-making and trend analysis from longitudinal patient data. Q Bio positions itself as a platform provider for clinics and longevity-focused partners seeking to offer preventive health services beyond standard physical examinations. The company has deployed its system at its own clinic and reports successful integration at other major longevity partners. The team comprises PhDs, MScs, and MDs from world-class institutions. The service model includes concierge scheduling, fast results delivery via personalized health dashboard, and post-exam consultation with Q Bio physicians. The platform is designed to be embedded into existing clinic workflows and integrated health stacks.

Talshir Medical Technologies Ltd., operating as RevitalVision, develops FDA-cleared perceptual learning and vision training software designed to improve the brain's visual processing. RevitalVision is indicated for amblyopia (lazy eye) in patients aged 9 and older, making it the only FDA-cleared product with efficacy claims for adult amblyopia as a standalone therapy without upper age limits. The platform uses proprietary perceptual learning technology supported by randomized controlled, double-blind clinical studies published in peer-reviewed journals. Beyond amblyopia treatment, RevitalVision addresses post-cataract surgery vision recovery, low myopia, presbyopia (read without glasses), sports vision enhancement, post-LASIK vision improvement, and low vision from eye diseases. Clinical evidence demonstrates an average 2.5-line improvement on ETDRS visual acuity charts, 100% improvement in contrast sensitivity (FACT sine wave), and enhanced stereo and binocular functions. The company operates a B2B2C model where ophthalmologists, optometrists, orthoptists, and optometry doctors subscribe to monthly or annual plans, then offer therapy programs to patients. Training sessions are administered at-home (3–4 per week) with periodic in-clinic assessments. The American Medical Association has assigned two unique CPT codes (0687T and 0688T) for RevitalVision amblyopia therapy, effective January 2022, supporting insurance coverage pathways. More than 30 clinical studies across the USA, Europe, and Asia support efficacy, with 12 published in peer-reviewed journals. The company operates globally with approximately 400 clinics and 15,000 treated patients reported.

VUNO Med, Inc. develops AI-driven diagnostic and patient monitoring software solutions for healthcare providers. The company manufactures two principal FDA-cleared products: VUNO Med®-DeepCARS®, an early warning system for cardiac arrest risk assessment in general ward inpatients using vital signs monitoring (heart rate, blood pressure, respiratory rate, oxygen saturation, plus age and timing); and VUNO Med®-Chest X-ray™ Triage, an AI-based diagnostic support system for detecting suspected chest abnormalities and major pulmonary diseases from chest radiography. Both products integrate deep learning algorithms with clinical workflows to assist healthcare professionals in reducing response times, lowering clinical costs, and improving patient outcomes. The DeepCARS system has been prospectively validated in multicentre studies published in peer-reviewed journals including Critical Care Medicine and Resuscitation, demonstrating predictive value for in-hospital cardiac arrest and unplanned ICU transfer. The Chest X-ray Triage system has undergone external validation for detection of nodular and reticular opacities in interstitial lung disease and other pulmonary conditions. VUNO distributes its solutions primarily to hospitals and health systems in the United States and maintains clinical advisory relationships with leading academic medical centers. The company emphasizes regulatory compliance and clinical evidence to support adoption in acute care settings.

VirtuSense is a healthcare technology company specializing in spatial artificial intelligence solutions for acute care environments. The company's flagship product, VSTOne®, is a single-source platform designed to bring hospital rooms into the future through autonomous patient monitoring and clinical decision support. VSTOne operates on a 99.99% accuracy rate and integrates with Epic MyChart to assist clinicians and patients. The platform addresses multiple clinical use cases within a single device, including autonomous fall prevention monitoring, pressure injury prevention, patient monitoring with hybrid human/AI capabilities, virtual nursing with ambient listening and automated clinical note capture, in-room patient AI assistance, violent patient alerting, and real-time location services (RTLS) with handwashing compliance tracking. The solution is designed to eliminate never events and simplify hospital workflows by enabling passive monitoring while clinicians focus on active care tasks. VirtuSense serves a diverse continuum of care including health systems, hospitals, primary care, skilled nursing facilities, assisted living, memory care, and therapy providers. The company reports significant clinical and operational impact, including fall prevention, reduction in false alarms, and measurable medical cost savings. VirtuSense serves major healthcare institutions including Cleveland Clinic, NYU Langone Health, UNC Health, and Mercy Health, among others.

Caris Life Sciences is a precision medicine and AI-driven TechBio company founded in 2008, headquartered in Phoenix, Arizona. The company specializes in molecular profiling and oncology diagnostics, operating a CLIA-certified laboratory that has processed over 1 million cases and 6.5 million tests. Caris develops comprehensive genomic and transcriptomic assays combining whole exome sequencing (WES), whole transcriptome sequencing (WTS), and protein analysis across 23,000+ genes. The company offers two primary clinical offerings: Caris Assure, a blood-based liquid biopsy utilizing circulating nucleic acid sequencing (cNAS) for pan-cancer profiling, and Caris MI Profile, a tissue-based assay delivering DNA, RNA, and protein analysis with AI-predictive algorithms. Caris maintains one of the largest multimodal databases globally—over 740,000 matched molecular and clinical outcomes records—which powers its proprietary Molecular AI platform. This AI engine generates 220+ interpretations and has measured over 50 billion molecular markers. The company serves oncologists, cancer patients, and biopharma partners across the care continuum: disease detection, therapy selection, and treatment monitoring. Caris publishes extensively (1,200+ peer-reviewed publications) and maintains partnerships with 45+ NCI-Designated Cancer Centers and 95+ members worldwide. The platform enables personalized, precision-oncology treatment decisions by revealing molecular blueprints and predicting individual patient response to therapies.

New Lantern is a cloud-native unified radiology platform that combines worklist management, PACS image viewing, and AI-powered reporting into a single browser-based workspace. The platform eliminates the need for radiologists to log into multiple separate systems; instead, all clinical functions—case selection, image analysis, and report generation—occur within one integrated application. The platform features three core components: (1) Intelligent Worklist, which automatically prioritizes cases by STAT status, modality, and assignment across multiple sites with zero manual intervention and automatic study precaching; (2) Ultra-fast Cloud Viewer, a sub-second DICOM viewer with intelligent precaching, hanging protocol learning, and full 3D and specialty modality support accessible from any browser on any device without VPN or local installation; and (3) Curie AI Reporting, a clinical decision-support tool that pre-drafts structured radiology reports in the radiologist's own dictation style, learning from edits over time while keeping the radiologist fully in control of review and sign-off. New Lantern is a complete PACS replacement, not an overlay system. Historical imaging data migrates with full continuity, preserving prior studies and reports. The platform integrates natively with major EHR systems including Epic and Oracle Health via HL7 and FHIR standards, with reports flowing directly into the EHR upon radiologist sign-off. Implementation is rapid (4–8 weeks for full deployment) with no on-premises server provisioning or hardware installation required. New locations can go live in days. The company is FDA-registered as a medical device and maintains enterprise-grade security controls and Business Associate Agreements. Radiologists report approximately $200K in incremental annual revenue per practitioner through improved workflow efficiency and TAT reduction.

OK2StandUP Inc. develops an AI-powered wearable patient monitoring system designed to predict and alert clinical staff of a patient's intention to sit up or change position within 6 seconds, supporting fall prevention protocols in hospitals, skilled nursing facilities, rehabilitation centers, and memory care communities. The system employs machine learning algorithms to detect movement patterns associated with sit-up intent, generating real-time notifications to care teams while minimizing false alarms (averaging 0.1 per bed per day). The technology is worn by patients and integrates into existing workflows without requiring cameras or one-on-one sitters, supporting evidence-based fall prevention strategies and reducing unnecessary room checks. Clinical feasibility studies across five nursing homes involving 44 high fall-risk residents over 4,500 monitoring hours reported zero falls during monitoring periods and 95% accuracy in intent detection. The system targets workflow integration for rounding, fall risk assessment, and mobility monitoring protocols. OK2StandUP serves healthcare systems, nursing homes, rehabilitation facilities, and memory care operators seeking non-invasive, AI-augmented patient safety solutions. The company is positioned for partnerships with OEM vendors seeking AI service layers and with clinical leaders implementing comprehensive fall prevention strategies.

Merative is a healthcare software and data analytics company offering integrated solutions across clinical imaging, data management, clinical decision support, and health services delivery. The company operates through five primary product lines: Merge (medical imaging and PACS solutions), Micromedex (evidence-based clinical decision support), Truven (healthcare data and analytics), Cúram (health and human services platform for benefits delivery and case management), and Zelta (cloud-based clinical trial data management). Merge provides enterprise imaging platforms, PACS systems, workflow orchestration, and imaging analytics serving 6 of 10 top U.S. health systems and 10 of 20 top U.S. hospitals across 5,500+ sites globally. Micromedex delivers medication-related clinical decision support used by healthcare providers for 40+ years. Truven serves 7 of 10 top U.S. payers and 40% of Fortune 100 employers with healthcare business intelligence and predictive analytics. Cúram supports 970+ social programs across government agencies, processing benefits for 187 million people globally with 200,000+ caseworker users. Zelta supports clinical development with 4,500+ studies across all phases including 500+ Phase III trials. The company serves healthcare systems, payers, employers, government agencies, pharmaceutical sponsors, CROs, and academic medical centers across 80+ countries. Products feature cloud-based deployment, workflow automation, real-world evidence integration, and interoperability with major healthcare IT systems.